PROF Archives - Page 2 of 7

Developments

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

In a 13G filed with the SEC today, accomplished businessman and founder of namesake transportation company Daseke (NADAQ:DSKE), Don Daseke, disclosed he has taken a 5.2% ownership stake in Profound Medical (NASDAQ:PROF)...

January 12, 2024

Developments

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical (NASDAQ:PROF; TSX:PRN) reported that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded TULSA’s HCPCS C code, C9734, for use in the ambulatory surgical center (ASC) setting...

November 3, 2023

Developments

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...

October 13, 2023

Developments

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

Profound Medical (NASDAQ:PROF; TSX:PRN) received FDA 510(k) clearance for its Thermal Boost module for use in conjunction with TULSA-PRO. Thermal Boost enables predictable, customized ablation at the prostate capsule...

September 25, 2023

Markets

RJ ups Profound Medical to strong buy

Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...

September 18, 2023

Markets

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...

June 5, 2023

Developments

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...

June 2, 2023

Developments

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET. The...

May 30, 2023

Developments

Profound Medical’s TULSA procedure featured at AUA

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...

May 1, 2023

Developments

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

Y. Mark Hong, M.D., a key opinion leader (KOL) and world recognized urologist, suggests that if physicians aren’t offering or at least talking to their prostate cancer patients about Profound Medical’s (NASDAQ:PROF;...

April 11, 2023

Tag - PROF

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

RJ ups Profound Medical to strong buy

Research Capital ups Profound Medical to speculative buy; PT to $17.25

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Profound Medical’s TULSA procedure featured at AUA

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

General

More